Clinical Trial: RENEW-SHCS: Safety and Immunogenicity of a Recombinant HIV Env Protein Vaccine in ARV-treated Adults Living With HIV in the SHCS

U.S., Aug. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07769983) titled 'RENEW-SHCS: Safety and Immunogenicity of a Recombinant HIV Env Protein Vaccine in ARV-treated Adults Living With HIV in the SHCS' on Jan. 13, 2025.

Brief Summary: A vaccine trial in which people with HIV-1 participating in the Swiss HIV Cohort Study will receive a HIV-specific vaccine to stimulate antibodies against HIV while continuing their standard antiretroviral therapy

Study Start Date: Jan. 27, 2025

Study Type: INTERVENTIONAL

Condition: People Living With HIV Antibody Response

Intervention: BIOLOGICAL: The Patients will all receive a vaccination with a recombinant HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 vaccine, a...